The global next-generation sequencing market size was valued at USD 12.65 billion in 2025 and is projected to grow from USD 14.93 billion in 2026 to USD 56.24 billion by 2034, registering a CAGR of 18.03% during the forecast period from 2026 to 2034. North America dominated the next-generation sequencing market with a market share of 42% in 2025.
The next-generation sequencing market is evolving through a shift toward clinically actionable, high-resolution genomic insights rather than purely exploratory research applications. Growth is being shaped by increasing use of ultra-deep sequencing for minimal residual disease detection and the rising role of sequencing in validating cell and gene therapies. Emerging portable and real-time sequencing technologies are expanding use cases beyond centralized laboratories into decentralized and field settings. At the same time, integration of multi-omics data is enhancing disease interpretation capabilities. Challenges around data interpretation complexity persist, yet advancements in automated bioinformatics and scalable workflows are enabling broader clinical adoption and operational efficiency across diverse healthcare and research environments.
Download a Free Sample To learn more about this report,
Growing Adoption of AI-Driven Genomic Analysis and Precision Medicine
The next-generation Sequencing market trends are being driven by the increasing use of genomic testing in precision medicine, cancer diagnostics, rare disease detection, and infectious disease surveillance. Healthcare providers and research institutions are adopting next-generation sequencing (NGS) to analyze large volumes of genetic data quickly and accurately, enabling earlier diagnosis and more personalized treatment decisions. Artificial intelligence (AI) and cloud-based bioinformatics platforms are also improving the interpretation of sequencing data, reducing analysis time, and supporting faster clinical decision-making. In addition, declining sequencing costs and advances in high-throughput sequencing technologies are expanding the use of NGS in clinical laboratories, pharmaceutical research, and population genomics. Growing investments in national genome sequencing programs and precision healthcare initiatives are further accelerating the adoption of NGS technologies worldwide.
These developments indicate that artificial intelligence, precision medicine, high-throughput sequencing, and advanced bioinformatics will remain the key Next-generation Sequencing market trends, improving genomic research, enabling personalized treatment, and driving long-term growth across clinical and research applications.
Increasing Adoption of Precision Medicine and Genomic Research
The next-generation sequencing market is expanding due to the growing adoption of precision medicine and increasing investments in genomic research. Healthcare providers and research institutions are utilizing next-generation sequencing technologies for cancer diagnostics, rare disease identification, infectious disease surveillance, and reproductive health applications. Continuous advancements in sequencing platforms, bioinformatics, and data analytics are improving sequencing accuracy while reducing turnaround time. These developments are significantly contributing to next-generation sequencing market growth as demand for personalized healthcare and large-scale genomic studies continues to increase worldwide.
High Sequencing Costs and Complex Data Analysis
The next-generation sequencing market faces challenges due to the high cost of sequencing instruments, sample preparation, and complex bioinformatics analysis. Although sequencing costs have declined significantly over the years, implementing advanced sequencing workflows still requires substantial investment in laboratory infrastructure and skilled professionals. In addition, managing and interpreting large genomic datasets remain technically challenging for many healthcare institutions. Recent next-generation sequencing market analysis indicates that these factors continue to limit adoption, particularly among smaller laboratories and healthcare providers in developing regions.
Expanding Clinical Applications and AI-Driven Genomics
The next-generation sequencing market is expected to benefit from expanding clinical applications in oncology, infectious diseases, pharmacogenomics, and prenatal screening. Increasing integration of artificial intelligence and machine learning into genomic analysis is improving variant interpretation, disease prediction, and personalized treatment planning. Growing government funding for national genome sequencing programs and precision medicine initiatives is also creating new opportunities for industry participants. These developments are expected to strengthen the next-generation sequencing market size by accelerating clinical adoption and expanding genomic research across global healthcare systems.
Managing Large Genomic Datasets and Regulatory Compliance
The next-generation sequencing market continues to face challenges related to genomic data management, cybersecurity, and compliance with evolving regulatory standards. Sequencing laboratories must securely store, process, and share large volumes of genomic data while protecting patient privacy and ensuring regulatory compliance. Maintaining interoperability between sequencing platforms, laboratory information systems, and healthcare databases also remains a significant operational challenge. According to recent next-generation sequencing market reports, companies are investing in scalable cloud infrastructure, AI-powered analytics, and advanced data security technologies to improve workflow efficiency and support broader clinical adoption.
Request Customizationto receive a tailored report.
WGS Segment is Projected to Register the Fastest Growth at a CAGR of 22.4%
The WGS segment is projected to register the fastest growth at a CAGR of 22.4% during 2026–2034. In 2025, the segment accounted for 33% of the global next-generation sequencing market, with a value of USD 4.17 billion. Growth is driven by the increasing adoption of comprehensive genomic analysis, declining sequencing costs, and expanding applications in precision medicine and disease research. Continuous advancements in sequencing platforms and bioinformatics are expected to further accelerate the segment's growth.
The targeted sequencing & resequencing segment dominated the market owing to its high accuracy, cost-effectiveness, and widespread use in clinical diagnostics and research applications. The whole exome sequencing segment continues to witness strong demand as it enables efficient identification of disease-related genetic variants while reducing sequencing complexity and costs.
The others segment includes emerging sequencing technologies developed for specialized genomic applications. Ongoing innovation and increasing research activities continue to support the adoption of these advanced sequencing approaches.
Consumables Segment is Projected to Register the Fastest Growth at a CAGR of 22.5%
The consumables segment is projected to register the fastest growth at a CAGR of 22.5% during 2026–2034. In 2025, the segment accounted for 43% of the global next-generation sequencing market, with a value of USD 5.44 billion. Growth is driven by the recurring demand for reagents, sequencing kits, and laboratory supplies required for every sequencing workflow. Increasing sequencing volumes and expanding genomic research activities are expected to further strengthen the segment's growth.
The platform segment continues to maintain a significant market presence owing to increasing investments in advanced sequencing instruments that deliver higher throughput, accuracy, and automation. The sample preparation segment is witnessing steady growth as efficient sample processing remains essential for obtaining reliable sequencing results. The target enrichment segment is gaining traction due to its ability to improve sequencing efficiency by focusing on specific genomic regions of interest.
The others segment includes supporting products and accessories that enhance sequencing workflows and laboratory operations. Continuous technological advancements and growing laboratory automation continue to drive demand for these products.
Oncology Segment is Projected to Register the Fastest Growth at a CAGR of 23.2%
The oncology segment is projected to register the fastest growth at a CAGR of 23.2% during 2026–2034. In 2025, the segment accounted for 36% of the global next-generation sequencing market, with a value of USD 4.55 billion. Growth is driven by increasing adoption of precision oncology, rising demand for biomarker discovery, and expanding use of genomic profiling for personalized cancer treatment. Continuous advancements in cancer genomics and targeted therapies are expected to further accelerate segment growth.
The clinical investigation segment continues to witness strong demand as next-generation sequencing is increasingly used to identify genetic disorders and support personalized treatment decisions. The reproductive health segment is expanding steadily due to growing adoption of prenatal screening, carrier testing, and reproductive genetic diagnostics. The metagenomics, epidemiology & drug development segment is gaining traction as sequencing technologies play a vital role in infectious disease surveillance, microbiome research, and pharmaceutical innovation.
The HLA typing/immune system monitoring segment remains an important application for transplant compatibility testing and immune response analysis. The agrigenomics & forensics segment continues to support advancements in crop improvement, livestock breeding, and forensic investigations. The consumer genomics segment is witnessing growing adoption as individuals increasingly seek genetic insights related to ancestry, health risks, and personal wellness.
NGS Data Analysis Segment is Projected to Register the Fastest Growth at a CAGR of 23.4%
The NGS data analysis segment is projected to register the fastest growth at a CAGR of 23.4% during 2026–2034. In 2025, the segment accounted for 27% of the global next-generation sequencing market, with a value of USD 3.42 billion. Growth is driven by the increasing volume of genomic data, rising adoption of artificial intelligence and cloud-based bioinformatics platforms, and growing demand for accurate genomic interpretation. Continuous improvements in computational tools are expected to further strengthen the segment's growth.
The sequencing segment dominated the market owing to the increasing deployment of high-throughput sequencing platforms capable of delivering rapid and accurate genomic data. The pre-sequencing segment continues to witness steady demand as sample collection, extraction, and library preparation remain critical steps for ensuring high-quality sequencing outcomes.
Hospitals & Clinics Segment is Projected to Register the Fastest Growth at a CAGR of 23.6%
The hospitals & clinics segment is projected to register the fastest growth at a CAGR of 23.6% during 2026–2034. In 2025, the segment accounted for 20% of the global next-generation sequencing market, with a value of USD 2.53 billion. Growth is driven by increasing integration of genomic testing into routine clinical practice, rising adoption of precision medicine, and expanding use of sequencing technologies for disease diagnosis and treatment planning. Improvements in healthcare infrastructure and accessibility continue to support segment growth.
The academic research segment dominated the market owing to extensive investments in genomic research, disease biology studies, and large-scale sequencing projects conducted by universities and research institutions. The clinical research segment continues to witness strong demand as sequencing technologies support biomarker discovery, clinical trials, and translational medicine. The pharma & biotech entities segment is expanding steadily due to increasing use of next-generation sequencing in drug discovery, companion diagnostics, and therapeutic development.
The other users segment includes government laboratories, public health organizations, and specialized research centers that utilize sequencing technologies for surveillance programs, population genomics, and various scientific research initiatives.
Speak to an Analystto discuss market opportunities.
North America next-generation sequencing market accounted for 42% of the global market, reaching USD 5.31 billion in 2025, and is projected to grow at a CAGR of 20.4% during the forecast period. The market is driven by increasing adoption of precision medicine, rising investments in genomic research, expanding applications in oncology and rare disease diagnosis, and strong government funding for sequencing technologies. Continuous technological advancements and well-established healthcare infrastructure further support regional market growth.
The US market was valued at USD 4.51 billion in 2025, making it the largest contributor in North America. Increasing demand for genomic testing, expanding precision medicine initiatives, rising investments in biotechnology research, and growing adoption of sequencing technologies in clinical diagnostics continue to drive market growth.
Canada's market reached USD 0.80 billion in 2025. Growing government support for genomics research, increasing adoption of next-generation sequencing in healthcare, expanding biotechnology collaborations, and rising demand for personalized medicine continue to support steady market expansion.
Europe next-generation sequencing market accounted for 27% of the global market, reaching USD 3.42 billion in 2025, and is projected to grow at a CAGR of 19.8% during the forecast period. Rising investments in genomic medicine, increasing research funding, expanding clinical applications of sequencing technologies, and supportive regulatory initiatives continue to strengthen regional market growth. Growing adoption of precision diagnostics further supports market expansion.
The UK market was valued at USD 0.68 billion in 2025. Increasing implementation of national genomics programs, expanding use of sequencing in disease diagnosis, growing investments in life sciences research, and rising adoption of personalized healthcare continue to support market growth.
Germany market accounted for USD 0.96 billion in 2025. Strong biotechnology research capabilities, increasing genomic testing, expanding precision medicine initiatives, and growing investments in advanced sequencing technologies continue to drive market expansion.
Asia Pacific next-generation sequencing market accounted for 22% of the global market, reaching USD 2.78 billion in 2025, and is projected to grow at a CAGR of 24.6% during the forecast period. Rapid expansion of healthcare infrastructure, increasing investments in genomics research, growing adoption of precision medicine, and rising prevalence of chronic diseases continue to accelerate regional market growth. Government initiatives supporting biotechnology innovation further strengthen market expansion.
Japan's market generated USD 0.50 billion in 2025. Increasing demand for advanced genomic testing, expanding precision medicine research, growing healthcare investments, and continuous technological innovation continue to support market growth.
China's market accounted for USD 1.17 billion in 2025, representing the largest share within Asia Pacific. Strong government support for genomics, expanding biotechnology industry, increasing adoption of sequencing technologies in clinical research, and growing investments in precision healthcare continue to drive market expansion.
Latin America next-generation sequencing market accounted for 5% of the global market, reaching USD 0.63 billion in 2025, and is projected to grow at a CAGR of 18.7% during the forecast period. Increasing investments in molecular diagnostics, expanding genomics research, growing healthcare modernization, and rising demand for personalized medicine continue to support regional market growth.
Brazil market accounted for USD 0.34 billion in 2025. Growing adoption of genomic technologies, increasing investments in life sciences research, expanding clinical diagnostics, and rising awareness of precision medicine continue to support market expansion.
Middle East & Africa next-generation sequencing market accounted for 4% of the global market, totaling USD 0.51 billion in 2025, and is projected to grow at a CAGR of 17.9% during the forecast period. Increasing investments in healthcare infrastructure, expanding adoption of molecular diagnostics, growing genomics research initiatives, and rising awareness of precision medicine continue to support regional market growth.
The UAE market was valued at USD 0.12 billion in 2025. Rising investments in advanced healthcare technologies, expanding genomics research programs, increasing demand for precision diagnostics, and growing government support for biotechnology innovation continue to drive market growth.
Africa's market reached USD 0.39 billion in 2025. Expanding access to genomic testing, increasing investments in healthcare research, growing adoption of molecular diagnostics, and improving healthcare infrastructure continue to create long-term growth opportunities across the region.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com